Annette Hayden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Annette Hayden has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alison A. Ritchie
University of Nottingham
1 shared publication - Andrew Cowie
Ex Vivo Cancer Pharmacology Centre of Excellence, Division of Cancer and Stem Cells, Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom. NG7 2RD.
1 shared publication - Anna M. Grabowskab
Ex Vivo Cancer Pharmacology Centre, Translational Medical Sciences, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK
1 shared publication - Antigoni Manousopoulou
Proteas Bioanalytics, The Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, California, USA
1 shared publication - Benjamin P. Sharpe
University of Southampton
1 shared publication - Ewan Kyle
Cancer Sciences Unit, Southampton General Hospital, Southampton, United Kingdom. SO16 6YD.
1 shared publication
Latest Publications
- Open Access
Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
Background and aims: Esophageal adenocarcinoma (EAC) is chemoresistant in the majority of cases. The tumor-promoting biology of cancer associated fibroblasts (CAF) make them a target for novel therapies. Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to regulate the activated fibroblast phenotype in benign disease. We investigated the potential for CAF modulation in EAC using PDE5i to enhance the efficacy of chemotherapy. Methods: EAC fibroblasts were treated with PDE5i and phenotypic effects examined using immunoblotting, immunohistochemistry, gel contraction, transwell invasion, organotypics, single cell RNAseq and shotgun proteomics. The combination of PDE5i with standard-of-care chemotherapy (Epirubicin, 5-Fluorouracil and Cisplatin) was tested for safety and efficacy in validated near-patient model systems (3D tumor growth assays (3D-TGAs) and patient derived xenograft (PDX) mouse models). Results: PDE5i treatment reduced α–SMA expression in CAFs by 50% (pin vitro and in vivo PDX-based model systems.
Open AccessModulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
Background and aims: Esophageal adenocarcinoma (EAC) is chemoresistant in the majority of cases. The tumor-promoting biology of cancer associated fibroblasts (CAF) make them a target for novel therapies. Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to regulate the activated fibroblast phenotype in benign disease. We investigated the potential for CAF modulation in EAC using PDE5i to enhance the efficacy of chemotherapy. Methods: EAC fibroblasts were treated with PDE5i and phenotypic effects examined using immunoblotting, immunohistochemistry, gel contraction, transwell invasion, organotypics, single cell RNAseq and shotgun proteomics. The combination of PDE5i with standard-of-care chemotherapy (Epirubicin, 5-Fluorouracil and Cisplatin) was tested for safety and efficacy in validated near-patient model systems (3D tumor growth assays (3D-TGAs) and patient derived xenograft (PDX) mouse models). Results: PDE5i treatment reduced α–SMA expression in CAFs by 50% (pin vitro and in vivo PDX-based model systems.